Roivant Sciences exec sells 200k shares post option exercise
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale. On 2026-07-27 he exercised stock options for 200,000 Common Shares at $3.85 per share from a fully vested award, leaving 4,044,834 options of this grant outstanding, expiring April 19, 2032. He then sold 200,000 Common Shares at a weighted average price of $34.95 (with trades between $34.62 and $35.56), with the filing indicating use of a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Venker Eric
Role
President & Immunovant CEO
Sold
200,000 shs ($6.99M)
Approx. gross sale proceeds
$6.99M
Approx. exercise cost
$770K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 200,000 | $0.00 | $0.00 |
| Exercise | Common Shares | 200,000 | $3.85 | $770K |
| Sale | Common Shares F1 | 200,000 | $34.95 | $6.99M |
Holdings After Transaction:
Stock Option (Right to Buy) — 4,044,834 contracts (Direct);
Common Shares — 1,613,063 shares (Direct)
Footnotes (2)
- F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Key Figures
Options exercised: 200000.0000 Common Shares
Shares sold: 200000.0000 Common Shares
Option exercise price: $3.8500 per share
+2 more
5 metrics
Options exercised
200000.0000 Common Shares
Stock options exercised at $3.8500 per share on 2026-07-27
Shares sold
200000.0000 Common Shares
Shares sold at weighted average $34.9500 per share on 2026-07-27
Option exercise price
$3.8500 per share
Conversion or exercise price of the reported stock option award
Weighted average sale price
$34.9500 per share
Weighted average of multiple trades between $34.62 and $35.56
Options remaining
4044834.0000 stock options
Derivative securities remaining after exercise; expire 2032-04-19
Key Terms
weighted average price, stock options, Power of Attorney
3 terms
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"Reflects an award of stock options to purchase Common Shares that is fully vested."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Power of Attorney regulatory
"Remarks include Exhibit 24 - Power of Attorney."
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Eric Venker report for Roivant Sciences (ROIV)?
Eric Venker reported exercising options for 200,000 Common Shares at $3.85 and then selling 200,000 Common Shares at a weighted average $34.95. All transactions occurred on 2026-07-27 and were indicated as made under a Rule 10b5-1 trading plan.
What options did Eric Venker exercise in Roivant Sciences (ROIV)?
He exercised stock options to purchase 200,000 Common Shares at an exercise price of $3.85 per share. The transaction reflects a fully vested stock option award with the options expiring on April 19, 2032, as disclosed in the footnote to the derivative transaction.
How many Roivant Sciences (ROIV) options does Eric Venker hold after this Form 4?
After the reported exercise, he holds 4,044,834 stock options of this grant. These derivative securities relate to Roivant Sciences Common Shares and are reported with an expiration date of April 19, 2032, indicating a substantial remaining option position.
Were Eric Venker’s Roivant Sciences (ROIV) trades under a Rule 10b5-1 plan?
Yes. The Form 4 indicates at least one reported transaction was effected under a Rule 10b5-1 trading plan. This checkbox confirmation suggests the timing of the option exercise and subsequent share sale followed a pre-established trading arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates